Corcept Therapeutics stock

CORT · NASDAQ · USD

Compare Corcept Therapeutics
$69.23Change from previous close: −5.09%Absolute change: −$3.72

Close · November 16, 2026

Price history

−7.85% over the period

1 year: from $75.12 (November 17, 2025) to $69.23 (November 16, 2026), −7.85%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026$69.23
October 30, 2026$81.12
September 30, 2026$115.23
August 31, 2026$113.35
July 31, 2026$114.49
June 30, 2026$86.95
May 29, 2026$69.49
April 30, 2026$46.52
March 31, 2026$40.31
February 27, 2026$35.70
January 30, 2026$39.87
December 31, 2025$34.80
November 28, 2025$79.40
November 17, 2025$75.12

At a glance

  • The company

    Biopharmaceutical company developing medications for severe endocrinologic, oncologic, metabolic and neurologic disorders

  • Latest results

    Quarter to September 30, 2026 · EPS $1.01 (estimate $0.79)

TickerLandia's take on Corcept Therapeutics

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$28.66
52-wk high$126.38

−45.22% from the 52-week high

Analysts · 5 analysts

Average target$141.00+103.68% vs. price

Buy 4 · Hold 0 · Sell 1 · Buy

TickerLandia Fingerprint: Corcept Therapeutics

Compared with similar companies: very high risk.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Corcept Therapeutics is pricier than in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), Corcept Therapeutics's P/E today is 84.4, above the median of its last 10 fiscal years (27.1; between 15.7 and 103.7 from 2016 to 2025). Corcept Therapeutics's P/E (trailing 12 months): 190.2, +213% against the median of a group of 6 similar companies (60.8).

P/E compared with its history

Compared with 6 similar companies

Corcept Therapeutics's metrics compared with similar companies
MetricCorcept TherapeuticsPosition in the groupBand
P/E (trailing 12 months)190.2High
Forward P/E16.5Middle
Operating margin0.8%Middle
ROE8.2%Middle
Debt/equity0.01Low

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Corcept Therapeutics. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$256.15M

Latest quarter · Q2 2026

Net income

$42.99M

Latest quarter · Q2 2026

Quarterly net margin

16.8%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$9.36B
P/E
190.2
EPS
$1.33
Volume
617.25K
Daily trading
€97.71M

How Corcept Therapeutics is changing

All results
  • Revenue grew 16.6% a year on average over the last 5 years

  • Operating margin fell from 28.0% to 5.9%

  • Profits turn into cash: free cash flow equal to 134% of net income

Returns

Corcept Therapeutics returns

$1,000 invested in Corcept Therapeutics 5 years ago, on November 16, 2021, would be worth $2,971 today: +197.10% in total, +24.34% per year. This is the price return only: dividends are excluded.

PeriodCorcept TherapeuticsS&P 500$1,000 becomes
1 month−37.16%−3.12%$628
6 months+22.80%+2.07%$1,228
Year to date+98.92%+10.46%$1,989
1 year−7.85%+13.33%$922
3 years+175.69%+67.73%$2,757
5 years+197.10%+60.86%$2,971
10 years+631.77%+247.35%$7,318

Over the last 6 months it has done better than 58% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Corcept Therapeutics: technical analysis

Corcept Therapeutics shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 44.0% below its all-time closing high ($123.57, August 25, 2026).

Trend
No clear trend
RSI (14 sessions)
23
Below 30: a strong fall in a short time
vs 200-session average
−9.68%

Active signals

  • Close below the low of the previous 55 sessions.

  • RSI below 30: the stock has fallen a lot in a short time.

    since October 23, 2026

Support and resistance

Price areas where Corcept Therapeutics has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$108.33+56.49%2 touches, last on September 18, 2026
  2. Resistance$89.50+29.29%2 touches, last on July 28, 2026
  3. Resistance$77.72+12.28%2 touches, last on June 22, 2026
  4. Last price$69.23
  5. Support$32.87−52.52%3 touches, last on March 13, 2026

Volatility and risk

Over the last year it has moved more than the S&P 500.

Beta (1 year) vs S&P 500
1.95
Volatility (60 sessions, annualised)
63.2%
Largest fall in the last year
−63.46%

In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Corcept Therapeutics: seasonality

Average monthly price change over 23 years

+2.1%Jan+0.8%Feb+14.0%Mar+0.6%Apr+2.5%May+5.3%Jun+0.9%Jul−0.7%Aug+6.1%Sep−2.0%Oct+1.9%Nov+3.0%Dec

Over the last 23 years, the strongest month for Corcept Therapeutics has been March: +14.03% on average, positive in 17 years out of 22. The weakest has been October: −1.98% on average, positive in 11 years out of 23. November, the current month, has been positive in 11 years out of 22 (+1.93% on average).

Show chart data
MonthAverageMedianPositive years
January+2.09%−0.26%11 of 22
February+0.83%−1.75%9 of 22
March+14.03%+7.51%17 of 22
April+0.62%+1.39%12 of 22
May+2.51%+2.82%12 of 23
June+5.29%−1.80%11 of 23
July+0.86%−5.10%11 of 23
August−0.68%−1.00%9 of 23
September+6.12%−0.70%11 of 23
October−1.98%−1.86%11 of 23
November+1.93%+3.88%11 of 22
December+2.97%−0.84%9 of 22

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Corcept Therapeutics and its competitors

With 730 employees, Corcept Therapeutics develops medicines that modulate cortisol activity for conditions linked to excess cortisol. Its marketed product, Korlym, is prescribed in the United States to control blood sugar in adults with Cushing's syndrome who have type 2 diabetes or impaired glucose tolerance and who either did not respond to surgery or cannot undergo it. The pipeline includes relacorilant for hypercortisolism, miricorilant, which is in a Phase 1b study for metabolic dysfunction-associated steatohepatitis, and several cortisol modulators, among them dazucorilant, for Lou Gehrig's disease.

Headquarters
Redwood City, United States
Employees
730
Founded
1998
Chief executive
Joseph Belanoff
Corcept Therapeutics and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Corcept TherapeuticsCORT$9.36B0.8%190.2+22.80%
Twist BioscienceTWST$7.4B-28.8%—+113.09%
Madrigal PharmaceuticalsMDGL$9.93B-10.7%—−18.72%
ImmunityBioIBRX$6.4B-150.2%—−24.28%
BioMarin PharmaceuticalBMRN$11.09B16.3%146.8+12.23%
Summit TherapeuticsSMMT$11.32B0.0%—−28.81%

Same industry or related industries, similar size. Compare Corcept Therapeutics with its competitors · Full profile